Discontinued — last reported Q1 '26
Merck & Co. Winrevair — Sales decreased by 43.9% to $525.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.3%, from $560.00M to $525.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates successful market penetration and growing demand, while a decrease may signal competitive pressure or loss of market share.
This metric measures the total gross revenue generated from the commercial sale of a specific pharmaceutical product wit...
Standard across the pharmaceutical industry as product-level revenue reporting, comparable to top-line sales figures for specific blockbuster drugs at peer companies.
mrk_segment_winrevair_sales| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $140.00M | $299.00M | $399.00M | $560.00M | $671.00M | $720.00M | $935.00M | $525.00M |
| QoQ Change | — | — | — | — | — | — | — | — | +113.6% | +33.4% | +40.4% | +19.8% | +7.3% | +29.9% | -43.9% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | +379.3% | +140.8% | +134.3% | -6.3% |